CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue, net	$ 8,973	$ 2,178	$ 16,487	$ 5,279
Operating expenses:
Costs of goods sold, including related party expenses of $359 and $87, respectively, and $659 and $211, respectively	4,786	2,005	9,699	4,821
Selling, general and administrative, including related party expenses of $125 and $123, respectively, and $250 and $246, respectively	32,450	13,972	70,156	25,917
Research and development, including related party expenses of $57 and $64, respectively, and $119 and $130, respectively	5,523	5,592	12,933	9,968
Amortization of intangible assets	566	566	1,133	1,133
Total operating expenses	43,325	22,135	93,921	41,839
Loss from operations	(34,352)	(19,957)	(77,434)	(36,560)
Change in the fair value of earnout liability	18,812		52,681
Change in the fair value of convertible promissory notes			(156)
Change in the fair value of warrants	2,600	(4,977)	6,084	(7,051)
Interest expense, net	(186)	(227)	(321)	(588)
Other income, net	613	422	930	891
Loss before income taxes	(12,513)	(24,739)	(18,216)	(43,308)
Provision for income taxes				17
Net loss	(12,513)	(24,739)	(18,216)	(43,325)
Accretion of Legacy Gelesis senior preferred stock to redemption value		(82,365)	(37,934)	(116,126)
Accretion of noncontrolling interest put option to redemption value	(85)	(96)	(173)	(190)
Net loss attributable to common stockholders	$ (12,598)	$ (107,200)	$ (56,323)	$ (159,641)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.17)	$ (19.18)	$ (0.83)	$ (28.54)
Weighted average common shares outstanding - basic and diluted	72,423,043	5,589,728	67,609,838	5,592,911
Product Revenue, Net
Revenue:
Total revenue, net	$ 8,973	$ 2,178	$ 16,487	$ 5,279